Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer.
Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer. Oncol Nurs Forum. 2019 Jan 13;46(1):E38-E47 Authors: Rodrigues Ferreira A, Farias Azevedo E Abstract PROBLEM IDENTIFICATION: Subcutaneous (SC) formulations for monoclonal antibodies (mAbs) must be evaluated for efficacy and safety in comparison with preexisting IV formulations to identify potential benefits and risks. LITERATURE SEARCH: This is a systematic review of clinical trials. MEDLINE®/PubMed, EMBASE, Cochrane Library, LILACS (Latin American and Caribbean Health Sciences Literature), and reference lists were searched for relevant studies. DATA EVALUATION: Data regarding efficacy and safety were registered in a form designed for this review. Risk of bias was assessed using the Jadad scale. SYNTHESIS: SC administration of alemtuzumab, trastuzumab, and rituximab presented therapeutic efficacy with similar safety profiles compared to their respective IV formulations, except for the higher prevalence of local adverse events following SC administration. IMPLICATIONS FOR PRACTICE: SC mAbs require slow administration (no less than five minutes), and the injection site should be changed at each cycle. Patient guidelines should include information about expected adverse effects, signs or symptoms of side effects requiring emergency care, and how to reduce potential discomfort caused by the injection. PMID: 30547957 [PubMed - in process]
Gastric cancer remains one of the most common causes of cancer deaths worldwide. The best current option for reducing gastric cancer deaths is Helicobacter pylori eradication combined with risk assessment and surveillance programs for those deemed to be at high risk for gastric cancer so as to identify lesions at a stage amenable to curative therapy. In this issue, Nam et al1 report a retrospective study of Helicobacter pylori eradication on gastric cancer incidence among 10,328 Korean adults undergoing health checkups including an H pylori test-and-treat program.
We read with great interest the comment by Dr Li and colleagues1 referring to our study on endoscopic full-thickness resection (EFTR) for early colorectal cancer.2 We would like to thank the editors for the opportunity to reply.
Gastric cancer remains one of the most common cancers worldwide and is the third leading cause of cancer-related mortality, trailing only lung and colon cancer.1 Given its historically low survival rates, early detection and resection is the most effective strategy to improve prognosis. Endoscopic submucosal dissection (ESD), a technique developed in Japan, enables en bloc resection of early gastric cancer (EGC) and can be curative for selected lesions, depending on the histologic features, size, and tumor depth.
We read with interest the article by Kuellmer et al1 evaluating endoscopic full-thickness resection (EFTR) for early colorectal cancer. The authors found that EFTR for early colorectal cancer was feasible and safe. Because their findings are important to current practice, several questions deserve attention.
We have read with great interest the study by Januszewicz et al1 describing the concept of endoscopist biopsy rate (EBR) as a potential quality indicator for routine diagnostic outpatient EGD. The authors found a significant variability in EBR among 26 endoscopists and an association between higher EBR, a higher detection of gastric precancerous conditions, and a lower risk of missed gastric cancers.1
AbstractPurposeFatigue is a common and distressing symptom in cancer patients which negatively affects patients ’ daily functioning and health-related quality of life. The aim of this study was to assess multidimensional fatigue in patients with brain metastases (BM) before, and after Gamma Knife radiosurgery (GKRS).MethodsPatients with BM, an expected survival > 3 months, and a Karnofsky Performance Status ≥ 70 and 104 Dutch non-cancer controls were recruited. The Multidimensional Fatigue Inventory (MFI), measuring general fatigue, physical fatigue, mental fatigue, reduced ac...
ConclusionsOur results suggest a role of decreased MPC1 copy number segments in reducing overall survival in glioblastoma. MPC1 deletion is associated with poor response to TMZ chemotherapy in GBM.
The USPSTF has upheld its'do not screen'recommendation for pancreatic cancer in the general population, but experts argue for screening for high-risk individuals.Medscape Medical News
ConclusionTogether these results emphasize an anti-tumorigenic role with a potential therapeutic value for PRL in HER-2 and luminal B breast cancer subtypes targeting the cancer stem-like cells.